News | May 10, 2021
Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The facility is expected to be completed in 2024
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Subscribe To Our Newsletter & Stay Updated
